Completed OBSERVATIONAL NCT04218435

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

Sponsor: Clinision

Conditions Heart Failure NYHA Class II Heart Failure NYHA Class IV

Interventions Sacubitril / Valsartan Oral Tablet

Updated 6 times since 2020 Last updated: Jan 29, 2021 Started: Jan 1, 2019 Primary completion: Oct 25, 2020 Completion: Dec 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Heart Failure NYHA Class II and Heart Failure NYHA Class IV and is currently completed. Clinision leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2021 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Recruiting
Aug 2020 — Jan 2021 [monthly]

Recruiting

▶ Show 1 earlier version

Feb 2020 — Aug 2020 [monthly]

Recruiting

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinision

Data source: Clinision

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan